Etid klinik pou BPCO nan Dallas, TX
12 etid pou BPCO ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Ap rekriteFaz 3
- IntraCare- Site Number : 8400034, Dallas
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Ap rekriteFaz 3
- Texas Health Presbyterian Hospital Dallas- Site Number : 8400032, Dallas
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
Ap rekrite
- University of Texas Southwestern, Dallas
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 2
- Research Site, Dallas
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Ap rekriteFaz 3
- Research Site, Dallas
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 2/3
- Alina Clinical Trials, LLC., Dallas
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 3
- Research Site, Dallas
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
Ap rekriteFaz 3
- GC2501 Study Site 109, Dallas
STRIVE Post-Market Registry Study
Ap rekriteEtid obsèvasyon
- Baylor Scott & White Research Institute, Dallas
- University of Texas Southwestern, Dallas
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Ap rekriteFaz 3
- GSK Investigational Site, Dallas
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Ap rekriteEtid obsèvasyon
- Liver Center of Texas, Dallas
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Ap rekriteFaz 3
- GSK Investigational Site, Dallas
Etid BPCO nan lòt vil
- Philadelphia, PA23 etid
- Miami, FL18 etid
- Birmingham, AL17 etid
- Boston, MA17 etid
- Orlando, FL15 etid
- Houston, TX15 etid
- Baltimore, MD14 etid
- Chicago, IL14 etid
- Pittsburgh, PA12 etid
- New York City, NY11 etid
- Ann Arbor, MI10 etid
- Detroit, MI9 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Ensifizyans kadyak42 etid
- Kansè Metastatik42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite31 etid
- Kansè ovè28 etid
- Kansè poumon27 etid
- Kansè vejik27 etid
- Kansè Endomèt24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.